Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04863014 |
| Consolidated Lead Sponsor | Regeneron Pharmaceuticals |
| Therapeutic Condition Cohort | Cardiovascular and Thrombosis |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 21 participants (ACTUAL) |
| Registered Start Date | 2021-07-12 |
| WhyStopped Classification | Strategic / Business / Sponsor Decision |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Yale Cancer Center and Smilow Cancer Hospital | New Haven, CT | Open Hospital Dossier -> |
| University of Kansas Medical Center | Kansas City, KS | Open Hospital Dossier -> |
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.